Ternary oxovanadium(IV) complexes of ONO-donor Schiff base and polypyridyl derivatives as protein tyrosine phosphatase inhibitors: synthesis, characterization, and biological activities.

Institute of Molecular Science, The Key Laboratory of Chemical Biology and Molecular Engineering of Education Ministry, Shanxi University, Taiyuan, China.
European Journal of Biochemistry (Impact Factor: 3.16). 04/2009; 14(6):841-51. DOI: 10.1007/s00775-009-0496-6
Source: PubMed

ABSTRACT A series of oxovanadium complexes with mixed ligands, a tridentate ONO-donor Schiff base ligand [viz., salicylidene anthranilic acid (SAA)], and a bidentate NN ligand [viz., 2,2'-bipyridine (bpy), 1,10-phenanthroline (phen), dipyrido[3,2-d:2',3'-f]quinoxaline (dpq), dipyrido[3,2-a:2',3'-c]phenazine (dppz), or 7-methyldipyrido[3,2-a:2',3'-c]phenazine (dppm)], have been synthesized and characterized by elemental analysis, electrospray ionization mass spectrometry, UV-vis spectroscopy, Fourier transform IR spectroscopy, EPR spectroscopy, and X-ray crystallography. Crystal structures of both complexes, [V(IV)O(SAA)(bpy)].0.25bpy and [V(IV)O(SAA)(phen)].0.33H(2)O, reveal that oxovanadium(IV) is coordinated with one nitrogen and two oxygen atoms from the Schiff base and two nitrogen atoms from the bidentate planar ligands, in a distorted octahedral geometry (VO(3)N(3)). The oxidation state of V(IV) with d(1) configuration was confirmed by EPR spectroscopy. The speciation of VO-SAA-bpy in aqueous solution was investigated by potentiomtreic pH titrations, and the results revealed that the main species are two ternary complexes at a pH range of 7.0-7.4, and one is the isolated crystalline complex. The complexes have been found to be potent inhibitors against human protein tyrosine phosphatase 1B (PTP1B) (IC(50) approximately 30-61 nM), T-cell protein tyrosine phosphatase (TCPTP), and Src homology phosphatase 1 (SHP-1) in vitro. Interestingly, the [V(IV)O(SAA)(bpy)] complex selectively inhibits PTP1B over the other two phosphatases (approximate ninefold selectivity against SHP-1 and about twofold selectivity against TCPTP). Kinetics assays suggest that the complexes inhibit PTP1B in a competitive and reversible manner. These suggest that the complexes may be promising candidates as novel antidiabetic agents.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Tetradentate Schiff base ligands (L), which were derived from the condensation of ethylenediamine with salicylaldehyde [Bis(5-bromosalicylaldehyde)ethylenediamine, bis(2-hydroxyacetophenone) ethylenediamine, Bis (benzoylacetone) ethylenediamine, Bis(2-hydroxy-1-napthaldehyde) ethylenediamine] and their complexes of VO3+ were synthesized and characterized by some physico-chemical studies; elemental, spectral (IR, UV, NMR), magnetic and conductance analyses. The elemental analysis data showed the formation of 1:1 [M:L] complexes. The obtained molar conductance values revealed their non- electrolytic nature. The results of magnetic measurements supported diamagnetic phenomenon for the complexes. The infrared spectral data displayed the main coordination sites of ligands towards VO3+ions. The electronic spectral results of the complexes showed π→π* (phenyl ring), n→π* (HC=N), CT transition. Based on analytical data octahedral geometry for the prepared complexes has been proposed. The antibacterial activity of the prepared complexes was also studied against some gram positive and gram negative bacteria, and a number of fungi. It is found that complexes are quite effective against tested bacteria whereas moderately effective to mycelia growth of the selected fungi.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Schiff base ligands 2-bromo-6-[(2-isopropylaminoethylimino) methyl]phenol (BP) and 2-ethoxy-6-[(2-isopropylaminoethylim ino))methyl]phenol (EP) and their copper(II) and nickel(II) complexes [Cu(BP)2(μ1,3-N3)]n·nClO4 (1) and [Ni(EP)2(dca)2] (2) (dca = dicyanamide), have been prepared and characterized by elemental analyses, IR, and single-crystal X-ray crystallographic determination. The crystal of (1) is triclinic: space group P , a = 7.666(2), b = 8.319(2), c = 13.395(3) Å, α = 90.023(2), β = 99.742(2), γ = 99.856(2)°, V = 829.1(3) Å3, Z = 1. The crystal of (2) is triclinic: space group P , a = 8.987(1), b = 9.480(1), c = 10.522(2) Å, α = 68.237(2), β = 71.906(2), γ = 82.816(2)°, V = 791.3(2) Å3, Z = 1. The Schiff bases coordinate to the metal atoms through phenolate O and imine N atoms. The metal atoms in the complexes are in octahedral coordination. The effect of the complexes on the antimicrobial activity against Staphylococcus aureus, Escherichia coli, and Candida albicans were studied.
    Synthesis and Reactivity in Inorganic Metal-Organic and Nano-Metal Chemistry 11/2013; 43(10). DOI:10.1080/15533174.2012.762789 · 0.52 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Based on the data about structure and antidiabetic activity of twenty seven vanadium and zinc coordination complexes collected from literature we developed QSAR models using the GUSAR program. These QSAR models were applied to 10 novel vanadium coordination complexes designed in silico in order to predict their hypoglycemic action. The five most promising substances with predicted potent hypoglycemic action were selected for chemical synthesis and pharmacological evaluation. The selected coordination vanadium complexes were synthesized and tested in vitro and in vivo for their hypoglycemic activities and acute rat toxicity. Estimation of acute rat toxicity of these five vanadium complexes was performed using a freely available web-resource ( It has shown that the selected compounds belong to the class of moderate toxic pharmaceutical agents, according to the scale of Hodge and Sterner. Comparison with the predicted data has demonstrated a reasonable correspondence between the experimental and predicted values of hypoglycemic activity and toxicity. Bis{tert-butyl[amino(imino)methyl]carbamato}oxovanadium (IV) and sodium(2,2'-Bipyridyl)oxo-diperoxovanadate(V) octahydrate were identified as the most potent hypoglycemic agents among the synthesized compounds.
    PLoS ONE 07/2014; 9(7):e100386. DOI:10.1371/journal.pone.0100386 · 3.53 Impact Factor

Full-text (2 Sources)

Available from
May 29, 2014